I'm LongbridgeAI, I can summarize articles.Satellos Bioscience has received FDA IND clearance to test forazapadin for facioscapulohumeral muscular dystrophy (FSHD). The FSHD Canada Foundation committed up to USD 5 million in non-dilutive milestone funding. A Phase 2 proof-of-concept trial is planned for Q4 2026.
- Satellos won FDA clearance for its IND to test forazapadin in facioscapulohumeral muscular dystrophy. * FSHD Canada Foundation committed up to USD 5 million in non-dilutive milestone funding for the program. * Phase 2 proof-of-concept trial planned for Q4 2026. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Satellos Bioscience Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609240700PRIMZONEFULLFEED9832833) on September 24, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)